Researchers have developed two new compounds that are able to inhibit SARS-CoV-2 main protease. The study reports one of the compounds is a strong drug candidate for further investigative trials in the treatment of coronavirus.
A new clinical trial is underway to test ibudilast, an asthma drug approved in Japan, for the treatment of severe COVID-19. Ibudilast is a MIF inhibitor. MIF is a gene that regulates immune response and is a driver of inflammation which results in the cytokine storm associated with coronavirus.
Macaque monkeys infected with mild-to-moderate coronavirus responded well to the antiviral Remdesivir. Researchers report the monkeys showed reduced clinical symptoms and less lung damage when the drug was administered. The findings back up other reports which claim the drug is effective at treating human COVID-19 infections in current clinical trials.
27 existing drugs which are currently not under evaluation for COVID-19 are effective at halting the replication of SARS-CoV-2. Four of the drugs, apilimod, MLN-3897, VBY-825, and ONO 5334, which have previously been tested for the treatment of a range of diseases from rheumatoid arthritis to cancer, appear to be the best candidates for coronavirus treatment.
Remdesivir, a drug initially developed to fight Ebola and currently being fast-tracked into trials for COVID-19, is highly effective at stopping the replication mechanism of coronavirus. The drug tricks the virus by mimicking its building blocks, causing the inhibitor to get incorporated repeatedly, and preventing replication of SARS-CoV-2.
Six potential drug candidates have been identified as candidates to treat COVID-19 infections. The drugs, which have previously been subjected to clinical trials for treating a range of conditions, from arthritis to cancer, target Mpro, the main SARS-CoV-2 enzyme.
Study warns of the potentially serious adverse effects of prescribing hydroxychloroquine and azithromycin for the treatment of COVID-19. Some of the potential side effects include cardiac arrhythmias, hypoglycemia, and neuropsychiatric effects.
hrsACE2, a genetically modified protein already being tested to prevent lung disease, reduces the viral growth of SARS-CoV-2 by a factor of 1,000 to 5,000 in human cell cultures. Researchers believe the enzyme copy lures the virus to attach itself to the copy, rather than human lung cells. The findings suggest hrsACE2 could significantly block the early stages of SARS-CoV-2 infections and prevent COVID-19 from becoming severe.
Researchers found no evidence NSAIDs, such as ibuprofen, may result in worse outcomes for some COVID-19 patients or help control the virus. TNF blockers and JAK inhibitors, used to treat inflammation and arthritis, were also found to be safe to use. However, low amounts of prednisolone or tacrolimus therapy may be useful in treating coronavirus infection.
Artificial IntelligenceDeep LearningFeaturedMachine LearningNeurologyNeuroscienceNeurotechOpen Neuroscience Articles··7 min read
A new deep learning algorithm helped researchers identify a powerful new antibiotic compound that kills many of the world's most problematic, disease-causing bacterias, including those which have so far been resistant to common antibiotics.
Sestrin, a naturally occurring compound, mimics many of the effects of exercise in mouse and fly models. The findings could help with the development of medications to help combat muscle wasting associated with aging and neurodegenerative diseases.
Fluoroquinolone antibiotics, such as Levofloxacin and Ciprofloxacin, appear to increase the risk of peripheral neuropathy by 47%. However, there is no significant increased risk of developing neuropathy associated with amoxicillin use.